Comparative Pharmacology
Head-to-head clinical analysis: AZSTARYS versus DEXTROAMPHETAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZSTARYS versus DEXTROAMPHETAMINE SULFATE.
AZSTARYS vs DEXTROAMPHETAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Increases extracellular levels of norepinephrine and dopamine by blocking reuptake and promoting release from presynaptic terminals, via trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 (VMAT2) inhibition.
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
5-60 mg/day orally divided every 4-6 hours, starting at 5 mg once or twice daily.
None Documented
None Documented
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
9-11 hours (adults); clinical context: twice-daily dosing achieves steady-state in ~2-3 days.
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Primarily renal (30-50% unchanged at acidic pH, less at alkaline pH); ~50% as metabolites (mostly deaminated and hydroxylated); minimal biliary/fecal.
Category C
Category D/X
CNS Stimulant
CNS Stimulant